---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Heterogeneity of treatment effect"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Heterogeneity of treatment effect. Topics: Dose response: high dose compared with low dose at 48 months, Baseline striatal volume as a predictor of progression in natural history data, Planned evaluation of treatment effect modification by subpopulation, Heterogeneity and subgroup analyses not planned, and 6 further topics. 11 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Summary

- Dose: the sponsor reports a difference between doses at 48 months in two statements. The third quarter 2026 release states that high-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC than low-dose patients. The four-year data release reports mean changes from baseline of –0.91 (high dose) and −1.94 (low dose) on cUHDRS, a difference of 1.03, and −0.30 and −0.70 on TFC, a difference of 0.40.
- Striatal volume: in natural history data presented with the AMT-130 analyses, baseline striatal volume predicted clinical progression in TRACK-HD and predicted cUHDRS decline in the absence of other covariates, and was no longer predictive of cUHDRS or TFC decline when propensity score adjustments were applied. A fourth cohort of six participants with lower striatal volumes than participants in previous cohorts received high-dose AMT-130, with dosing completed in the fourth quarter of 2025.
- Planned analyses: ICER's research protocol plans, data permitting, to evaluate treatment effect modification by HD stage (HD-ISS stages 2 and 3), concomitant antidopaminergic medication, and striatal volume. ICER's model analysis plan states that no heterogeneity and subgroup analyses are planned because currently available trial data are insufficient to support them. A public comment from Prilenia identified concomitant antidopaminergic medications as a pharmacologically important covariate that a chance imbalance in small studies can shift.
- Natural history: in a progression model, TFC progression in individuals with HD-ISS 2 is not expected to differ from that in HD-ISS 3, and progression rates correlate weakly between clinical scores. In 960 participants, longer disease duration and better cognitive status at baseline were associated with less rapid TFC decline.
- Other HD therapies: exploratory GENERATION HD1 analyses suggested benefit in younger participants with lower disease burden, but in GENERATION HD2 the biomarker effects did not translate into a meaningful clinical improvement. For pridopidine, post hoc analyses suggested benefit in participants not receiving antidopaminergic medications, and the European Medicines Agency noted that the validity and relevance of the subgroup results had not been demonstrated.

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf); [uniQure press release, third quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2025-financial-results-and); [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent); [ICER research protocol (2026)](https://osf.io/download/eyjx6/); [ICER model analysis plan (2026)](https://osf.io/download/puega/); [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf); [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/); [Marder et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10668713/); [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/); [EMA questions and answers on withdrawal of Nurzigma application (2025)](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_en.pdf)

<a id="topic-2.2.2.3-2"></a>

### Dose response: high dose compared with low dose at 48 months

> “At 48-months, high-dose patients compared to low-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC, consistent with a dose-dependent treatment effect.”

Source: [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-2.2.2.3-3"></a>

### Baseline striatal volume as a predictor of progression in natural history data

> “Baseline Striatal Volume is a Predictor of Clinical Progression in TRACK-HD”
> “Baseline Volumetric Criteria Predicts cUHDRS Decline in the Absence of Other Covariates”
> “Baseline Volumetric Criteria Are No Longer Predictive of TFC Decline When Propensity Score Adjustments are Applied”

Source: [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf)

<a id="topic-2.2.2.3-4"></a>

### Planned evaluation of treatment effect modification by subpopulation

> “Data permitting, we will evaluate the evidence for treatment effect modification by subpopulations defined by:”
> “Other relevant HD characteristics (e.g., HD staging [e.g., Huntington’s Disease Integrated Staging System (HD-ISS) stages 2 and 3], concomitant antidopaminergic medication, striatal volume, etc.)”

Source: [ICER research protocol (2026)](https://osf.io/download/eyjx6/)

<a id="topic-2.2.2.3-5"></a>

### Heterogeneity and subgroup analyses not planned

> “No heterogeneity and subgroup analyses are planned as currently available trial data are insufficient to support them.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-2.2.2.3-6"></a>

### Antidopaminergic medication as an effect modifier: public comment by Prilenia

> “Prilenia respectfully requests ICER consider the following:”
> “Concomitant antidopaminergic medications (ADMs) are a pharmacologically important covariate.”
> “In small sample size studies a chance imbalance in ADM use between groups can disproportionately shift group-level averages on functional scales, and limited statistical power constrains the ability to adjust for or stratify by ADM exposure, making it harder to distinguish a true treatment effect from an artifact of unbalanced background medication use.”

Source: [ICER public comments on draft scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Folio_092126.pdf)

<a id="topic-2.2.2.3-7"></a>

### Progression by subpopulation and endpoint: disease progression model

> “For instance, PIN and CAP can effectively enrich the population with patients more likely to progress, particularly when using TFC (Figure 5, A and B).”
> “Moreover, when using TFC as an end point, the progression rate in individuals with HD-ISS = 2 is not expected to be different from the rate in those with HD-ISS = 3, in contrast to other clinical measurements such as SMDT (Figure 5C).”
> “However, the weak correlation in progression rates between different clinical scores indicates that patients likely to progress based on one score may not necessarily progress based on other scores.”

Source: [Boareto et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12057022/)

<a id="topic-2.2.2.3-8"></a>

### Baseline covariates of functional decline: cohort of 960 participants

> “In multivariate analysis (n = 960), longer disease duration and better cognitive status at baseline were associated with a less rapid rate of decline in TFC score, whereas depressive symptomatology was the only factor associated with more rapid decline on the IS score.”

Source: [Marder et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10668713/)

<a id="topic-2.2.2.3-9"></a>

### Tominersen: exploratory subgroup finding tested in GENERATION HD2

> “GENERATION HD2 was initiated following exploratory analyses of the phase III GENERATION HD1 study, which suggested that younger participants with lower disease burden might derive benefit from lower-dose, less frequent administration of tominersen.”
> “After completion of the planned 16-month treatment period in all 301 participants, top-line analyses showed that tominersen was well tolerated and achieved significant reductions in mHTT protein and NfL concentrations compared with placebo.”
> “However, these biomarker effects did not translate into a meaningful improvement in clinical outcomes, and Roche therefore discontinued further clinical development of tominersen.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.2.2.3-10"></a>

### Pridopidine: post hoc subgroup without antidopaminergic medication

> “PRECISE-HD seeks to build on findings from numerous large trials of pridopidine in HD that failed to demonstrate efficacy, most recently the phase III PROOF-HD study (NCT04556656),”
> “Although the primary and key secondary endpoints (change in TFC and cUHDRS at week 65) were not met in the overall study population, post-hoc and sensitivity analyses suggested potential benefit among participants who were not receiving antidopaminergic medications.”

Source: [Farag et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13768560/)

<a id="topic-2.2.2.3-11"></a>

### Pridopidine (Nurzigma): regulator assessment of the subgroup analyses

> “The active substance in Nurzigma, pridopidine, activates a protein called sigma-1 receptor (S1R).”
> “The Agency noted that the validity and relevance of the results of the analyses in the subgroup of patients (adults with early Huntington’s disease who were not treated with antidopaminergic medicines) from the main study have not been demonstrated.”

Source: [EMA questions and answers on withdrawal of Nurzigma application (2025)](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-nurzigma-pridopidine_en.pdf)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
